ESMO 2018 | Mono or combination immunotherapy for HNSCC?

Name: Mono or combination immunotherapy for HNSCC?
Uploaded: 2018-10-26T16:54:17.000Z
Duration: 1 min 37 s
Description: Immunotherapy has come a long way in head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the use of these agents as monotherapies vs. their use in combinan moving forwards. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Ezra Cohen • 26 Oct 2018

ESMO 2018

Head and Neck Cancer Nivolumab Pembrolizumab

Immunotherapy has come a long way in head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the use of these agents as monotherapies vs. their use in combinan moving forwards. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.